Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Income towards Parent Company: 2019-2024

Historic Income towards Parent Company for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to -$337.7 million.

  • Relay Therapeutics' Income towards Parent Company rose 16.02% to -$74.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$296.8 million, marking a year-over-year increase of 14.03%. This contributed to the annual value of -$337.7 million for FY2024, which is 1.24% up from last year.
  • Relay Therapeutics' Income towards Parent Company amounted to -$337.7 million in FY2024, which was up 1.24% from -$342.0 million recorded in FY2023.
  • Relay Therapeutics' Income towards Parent Company's 5-year high stood at -$52.4 million during FY2020, with a 5-year trough of -$363.9 million in FY2021.
  • In the last 3 years, Relay Therapeutics' Income towards Parent Company had a median value of -$337.7 million in 2024 and averaged -$323.4 million.
  • Per our database at Business Quant, Relay Therapeutics' Income towards Parent Company spiked by 30.40% in 2020 and then tumbled by 594.25% in 2021.
  • Relay Therapeutics' Income towards Parent Company (Yearly) stood at -$52.4 million in 2020, then tumbled by 594.25% to -$363.9 million in 2021, then grew by 20.17% to -$290.5 million in 2022, then dropped by 17.72% to -$342.0 million in 2023, then climbed by 1.24% to -$337.7 million in 2024.